479 related articles for article (PubMed ID: 31993732)
1. Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.
Naoi M; Maruyama W; Shamoto-Nagai M
J Neural Transm (Vienna); 2020 Feb; 127(2):131-147. PubMed ID: 31993732
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies.
Naoi M; Maruyama W; Shamoto-Nagai M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232361
[TBL] [Abstract][Full Text] [Related]
3. Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson's disease.
Naoi M; Maruyama W; Shamoto-Nagai M; Riederer P
J Neural Transm (Vienna); 2024 Jun; 131(6):639-661. PubMed ID: 38196001
[TBL] [Abstract][Full Text] [Related]
4. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.
Naoi M; Maruyama W; Inaba-Hasegawa K
Expert Rev Neurother; 2013 Jun; 13(6):671-84. PubMed ID: 23739004
[TBL] [Abstract][Full Text] [Related]
5. Rasagiline and selegiline suppress calcium efflux from mitochondria by PK11195-induced opening of mitochondrial permeability transition pore: a novel anti-apoptotic function for neuroprotection.
Wu Y; Kazumura K; Maruyama W; Osawa T; Naoi M
J Neural Transm (Vienna); 2015 Oct; 122(10):1399-407. PubMed ID: 25863936
[TBL] [Abstract][Full Text] [Related]
6. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
[TBL] [Abstract][Full Text] [Related]
7. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
[TBL] [Abstract][Full Text] [Related]
8. ''70th Birthday Professor Riederer'' induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to a disease-modifying therapy?
Maruyama W; Naoi M
J Neural Transm (Vienna); 2013 Jan; 120(1):83-9. PubMed ID: 22892822
[TBL] [Abstract][Full Text] [Related]
9. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
J Neural Transm (Vienna); 2013 Mar; 120(3):435-44. PubMed ID: 22968599
[TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
11. Rasagiline, a suicide inhibitor of monoamine oxidases, binds reversibly to α-synuclein.
Kakish J; Tavassoly O; Lee JS
ACS Chem Neurosci; 2015 Feb; 6(2):347-55. PubMed ID: 25514361
[TBL] [Abstract][Full Text] [Related]
12. Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.
Petit GH; Berkovich E; Hickery M; Kallunki P; Fog K; Fitzer-Attas C; Brundin P
PLoS One; 2013; 8(4):e60691. PubMed ID: 23573275
[TBL] [Abstract][Full Text] [Related]
13. Disease-modifying treatment of Parkinson's disease by phytochemicals: targeting multiple pathogenic factors.
Naoi M; Maruyama W; Shamoto-Nagai M
J Neural Transm (Vienna); 2022 Jun; 129(5-6):737-753. PubMed ID: 34654977
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
Szökő É; Tábi T; Riederer P; Vécsei L; Magyar K
J Neural Transm (Vienna); 2018 Nov; 125(11):1735-1749. PubMed ID: 29417334
[TBL] [Abstract][Full Text] [Related]
15. Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons.
Sharma SK; Ebadi M
Antioxid Redox Signal; 2003 Jun; 5(3):251-64. PubMed ID: 12880480
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
Mandel S; Weinreb O; Amit T; Youdim MB
Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
[TBL] [Abstract][Full Text] [Related]
17. Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.
Naoi M; Maruyama W
Curr Pharm Des; 2010; 16(25):2799-817. PubMed ID: 20698822
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.
Abassi ZA; Binah O; Youdim MB
Br J Pharmacol; 2004 Oct; 143(3):371-8. PubMed ID: 15339864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
